Resolution criteria
This market will resolve to "Yes" if JRT (isotryptamine-LSD) is officially listed as an accepted intervention in any study cohort of the National Institute on Aging's (NIA) Interventions Testing Program (ITP) on or before December 31, 2031.
The primary source for resolution is the official ITP "List of Compounds Tested" or equivalent "Supported Interventions" page maintained by the NIA at https://www.nia.nih.gov/research/dab/interventions-testing-program-itp or the ITP Data Coordinating Center database. Inclusion in a study refers to the formal selection and commencement of testing protocols in the genetically heterogeneous (UM-HET3) mouse stock as defined by the ITP. If no such record exists by the specified date, the market will resolve to "No".
Background
The Interventions Testing Program (ITP) is a peer-reviewed, multi-institutional study funded by the National Institute on Aging (NIA) that systematically tests pharmacological interventions for their potential to extend lifespan and delay aging-related pathologies in genetically heterogeneous mice.
JRT (isotryptamine-LSD) is a synthetic analog of LSD developed by researchers at the University of California, Davis, in association with Delix Therapeutics. Described in scientific literature around 2025, JRT is characterized as a "psychoplastogen"—a compound designed to promote neuroplasticity—with preclinical studies suggesting antidepressant-like and pro-cognitive effects in animals, while exhibiting reduced hallucinogenic potential compared to LSD. As a potential neurotherapeutic agent, it is being investigated for conditions such as schizophrenia and other neuropsychiatric diseases.
This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.
1,000